News

BioGaia sees sales grow 22%

Probiotics company BioGaia has announced its full-year financial results. “A sales growth of 22% (including licence revenue from Nestlé 53 %) and an operating margin of 26% for the full year 2014, can only be summed up as a successful year,” said Peter Rothschild, CEO of BioGaia. “The fourth quarter showed even better growth than […]

Probiotics company BioGaia has announced its full-year financial results.

“A sales growth of 22% (including licence revenue from Nestlé 53 %) and an operating margin of 26% for the full year 2014, can only be summed up as a successful year,” said Peter Rothschild, CEO of BioGaia. “The fourth quarter showed even better growth than the full year and it is once again gratifying to see that almost all of our markets are growing at a solid pace and that the BioGaia brand is becoming increasingly established, particularly among paediatricians, as the safest and most effective probiotic on the market.”

Full year 2014
(Figures in brackets refer to the same period of last year)

• Net sales amounted to SEK 481.8 million (315.9), an increase of SEK 165.9 million (53 %). Net sales include license revenue of SEK 95.4 million from Nestlé. Excluding license revenue from Nestlé, net sales totalled SEK 386.4 million, an increase of 22% (excluding foreign exchange effects, 18%).
• Net sales in the Paediatrics Business Unit reached SEK 313.7¹ million (238.6), up by SEK 75.1 million (31%).
• Net sales in the Adult Health Business Unit amounted to SEK 69.4 million (75.6), a decrease of SEK 6.2 million (-8%).
• Operating profit was SEK 196.9 million (81.7), an increase of SEK 115.2 million (141%). Excluding license revenue from Nestlé, operating profit was SEK 101.5 million, an increase of 24% (excluding foreign exchange effects and operating expenses for the subsidiary IBT, 21%).
• Profit after tax was SEK 148.0 million (64.2), up by SEK 83.8 million (130%). Excluding license revenue from Nestlé, profit after tax was SEK 73.6 million, an increase of 15%.

Fourth quarter 2014

• Net sales reached SEK 121.4 million (90.2), an increase of SEK 31.2 million (35%) (excluding foreign exchange effects, 28%).
• Net sales in the Paediatrics Business Unit totalled SEK 97.8 million (65.6), an improvement of SEK 32.2 million (49%).
• Net sales in the Adult Health Business Unit amounted to SEK 23.0 million (24.1), a decrease of SEK 1.1 million (-4%).
• Operating profit was SEK 30.6 million (23.8), an increase of SEK 6.8 million (29 %) (excluding foreign exchange effects and operating expenses for the subsidiary IBT, 23%).
• Profit after tax was SEK 19.1 million (16.3), an improvement of SEK 2.8 million (17%).